Business Context and Reporting Period
This Form 8-K reports on the 2021 Annual Meeting of Stockholders held by Gemini Therapeutics, Inc. on September 29, 2021. The filing details the voting results for three proposals submitted to security holders. Note: The request metadata references "Disc Medicine, Inc.," but the filing text explicitly identifies the registrant as Gemini Therapeutics, Inc.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
As of the record date (August 2, 2021), there were 43,055,112 shares of common stock outstanding. A total of 28,632,671 shares (66.50%) were present or represented by proxy, establishing a quorum. The voting results were as follows:
- Proposal 1: Election of Class I Director
- Carl L. Gordon was elected.
- For: 18,344,313 votes
- Withheld: 8,445,896 votes
- Broker Non-Votes: 1,842,462
- Proposal 2: Approval of 2021 Employee Stock Purchase Plan
- Approved by stockholders.
- For: 25,338,796 votes
- Against: 1,437,862 votes
- Abstain: 13,551 votes
- Broker Non-Votes: 1,842,462
- Proposal 3: Ratification of Independent Registered Public Accounting Firm
- Ernst & Young was ratified for the fiscal year ending December 31, 2021.
- For: 28,491,832 votes
- Against: 38,498 votes
- Abstain: 102,369 votes
- Broker Non-Votes: 0
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, risk factors, or contingencies. It is a procedural report of the annual meeting outcomes.
Key Facts for Investor Verification
- Verify the registrant name is Gemini Therapeutics, Inc. (GMTX), not Disc Medicine, Inc.
- Confirm the election of Carl L. Gordon to the Board of Directors.
- Note the approval of the 2021 Employee Stock Purchase Plan, which may impact future dilution.
- Confirm Ernst & Young remains the independent auditor for the 2021 fiscal year.
- Review the proxy statement filed on August 17, 2021, for detailed background on the proposals.